Expiry Management in Clinical Trials: Winning the Race Against the Calendar

Every kit in a clinical trial is a melting asset. From the day of manufacture, a clock runs toward an expiry (or retest) date — and in early development, that clock is often brutally short, because shelf life can only be claimed as far as real-time stability data supports. The result is one of clinical supply's defining races: trials that run for years, supplied by drug that may start with months. Managed well, expiry is a scheduling problem. Managed passively, it becomes the silent destroyer of inventory — a major contributor to the overage and waste we dissected in our cost-drivers post — and, at its worst, a patient-facing supply failure wearing a date sticker.

Why do investigational drugs have such short shelf lives?

Because shelf life is earned, not assumed. A new molecule enters the clinic with whatever stability data exists — often 12 or 18 months of real-time evidence — and regulators allow labeled shelf life only as far as the data justifies. The stability program keeps running in parallel with the trial, and as each time point passes, the sponsor can typically extend the claimed shelf life. This creates the characteristic rhythm of clinical expiry management: drug is released short-dated, extensions arrive in steps, and the supply chain must continuously decide what to do with inventory whose usable life keeps being renegotiated mid-flight.

What happens when a shelf-life extension is approved?

The least appreciated workflow in clinical supply — and one of the most operationally intense. An approved extension must reach every affected kit, which means:

• Regulatory sequencing: the extension may need approval or notification country by country before stock there can be updated — the same batch can legally hold different expiry dates in different markets for a while.
• Relabeling logistics: kits carrying printed expiry dates need over-labeling at depots or sites — a controlled, documented, sometimes QP-overseen operation — or must be used up before their printed date regardless of the science.
• System updates: the IRT's expiry data must be updated in step with each country's approval, or the system will keep blocking (or wrongly allowing) kits against stale dates.

Smart programs design for this from the start: single-panel labels that omit printed expiry where regulations permit (holding the date in the IRT instead), e-label strategies where accepted, and pre-planned relabeling playbooks — because they know the extension is coming and the scramble is optional.

How does good expiry management actually reduce waste?

By putting the calendar inside every allocation decision:

1. First-expiry-first-out (FEFO), enforced by the system. Oldest usable stock ships first — automatically, via IRT logic, not via depot goodwill.
2. Expiry-aware assignment rules. A kit should only go to a patient if it will still be valid at the point of use (and, for multi-visit kits, through the dosing window). "Do-not-ship" and "do-not-dispense" windows encode this — set thoughtfully, they protect patients; set lazily wide, they strand perfectly good drug.
3. Batch-level demand matching. Allocate short-dated batches to fast-burning regions and long-dated batches to slow sites and long import lanes. Sending the shortest-dated stock on the longest journey is the classic self-inflicted write-off.
4. A standing expiry horizon review. A monthly look at what expires in the next 3–6 months versus forecast demand, with decisions attached: redeploy, prioritize, relabel-on-extension, or accept the loss early and cheaply rather than late and expensively.

Where does expiry management go wrong?

Predictably. Extensions approved but never propagated to the IRT or the labels, so usable drug is blocked or destroyed by administrative expiry. Deep site buffers of short-dated kits — the buffer-stacking problem with a countdown attached. Relabeling campaigns discovered late, executed under pressure, disrupting supply exactly when they were meant to preserve it. And the quiet one: nobody owning the batch calendar at program level, so each study team learns about the expiry cliff from a site email. The fix in every case is the same — treat expiry as a managed, forward-looking data stream with a named owner, not as a date that happens to inventory.